Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with ovarian, fallopian tube, or primary peritoneal cancer that has been confirmed by laboratory testing of tissue (high-grade serous type is preferred).
• People whose cancer has come back or stopped responding to treatment after at least two previous treatment courses, which should have included a platinum-based chemotherapy unless it was not medically suitable.
• People whose cancer can be measured on scans according to a standard set of measurement rules called RECIST v1.1.
• People whose tumor tissue (from a stored or fresh sample) shows high enough levels of at least two of the following proteins: mesothelin (MSLN), folate receptor alpha (FRα/FOLR1), or MUC16 (also known as CA-125).
• People who are generally well enough to carry out everyday activities with no more than minor limitations, based on a standard doctor-assessed fitness scale (ECOG score of 0 or 1).
• People whose blood counts and organ function meet certain minimum levels — including blood cell counts, liver function, kidney function, and bilirubin levels (confirm specific values with the trial site).
• Women who could become pregnant must have a negative pregnancy test, and must agree to use effective contraception for 12 months after the treatment infusion, or as directed by local gene therapy guidelines.
• People who are able to attend all required study visits and follow-up appointments, and who are willing to provide written consent to participate.

Who may not be able to join:

• People who have received a gene-modified cell therapy — such as CAR-T or CAR-NK therapy — within the past 6 months, or who have previously received any therapy targeting the same proteins this trial targets (confirm details with trial site).
• People who have active cancer spread to the brain or the lining around the brain or spinal cord that currently requires treatment.
• People who have an active, uncontrolled infection, including active tuberculosis or a significant viral infection that is not under control.
• People with HIV where the virus is not currently controlled, or who have active hepatitis B or hepatitis C with detectable virus levels at the time of screening.
• People with serious heart conditions, such as a recent heart attack, a heart rhythm problem that is not controlled, or significant heart failure (confirm with trial site).
• People who have an active autoimmune disease that required immune-suppressing medication within the past 30 days (low-dose steroid replacement therapy may still be acceptable — confirm with trial site).
• People who are currently receiving other cancer treatments such as chemotherapy, targeted therapy, or radiation, or who have not waited long enough since stopping those treatments as required by the trial rules (confirm washout periods with trial site).
• People who have had major surgery within 4 weeks before the start of the preparatory treatment phase of the trial (minor procedures may be acceptable — confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.